Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Eagle Pharmaceuticals Reports Third Quarter 2019 Results
November 12, 2019 6:51 AM EST-- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 --
-- Plan to initiate a clinical trial in December for Eagles innovative fulvestrant program, which has the potential to result in greater inhibition of estrogen receptors and better outcomes for patients with estrogen receptor-positive breast cancer --
-- Company returned to 2019 Hajj and enrolled additional EHS patients in its controlled clinical study --
-- Eagle expects to file a... More
